| ABSTRACT Objective: To systematically review the efficacy and safty of monosialoteterahexosyl ganglioside (GM1) in the treatment of hypoxic ischemic encephalopathy (HIE). Methods:PubMed, Clinical Trials, Cochrane Library, Embase, WanFang Data, CNKI and VIP databases were electronically searched to collect randomized controlled trials (RCTs) of GM1 in the treatment of HIE from inception to August 31th, 2018. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then Meta analysis was performed by RevMan 5.3 software. Results:A total of 14 RCTs involving 1 052 children with HIE were included. The results of Meta analysis showed that: the effective rate of HIE treatment was better than that of conventional treatment or conventional treatment combined with other neuroprotective drugs in the control group, whether alone (RR=1.35, 95%CI 1.21 to 1.51, P＜0.01) or in combination with GM1 (RR=1.20, 95%CI 1.07 to 1.35, P＜0.01). The neonatal behavioral neurological assessment (NBNA) (7d, 10 14d, 28d) was higher than that of the control group whether used alone or in combination. The incidence of abnormal head CT rate was lower than that of the control group (RR=0.34, 95%CI 0.18 to 0.61, P＜0.01). The incidence of long term sequelae was lower than that of the control group (RR=0.25，95%CI 0.12 to 0.52, P＜0.01). Conclusion:Based on the existing clinical evidence, GM1 may be a promising treatment option for HIE and is relatively safe. However, due to limited quality and quantity of the included studies, more high quality studies are required to verify above conclusions. |
